Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Clin Endocrinol Metab. 2011 Apr;96(4):E728-38. doi: 10.1210/jc.2010-2420. Epub 2011 Jan 20.
Massive macronodular adrenocortical disease or ACTH-independent macronodular adrenal hyperplasia (AIMAH) is a clinically and genetically heterogeneous disorder.
Whole-genome expression profiling and oligonucleotide array comparative genomic hybridization changes were analyzed in samples of different nodules from the same patients with AIMAH. Quantitative RT-PCR and staining were employed to validate the mRNA array data.
Chromosomal gains were more frequent in larger nodules when compared with smaller nodules from the same patients. Among the 50 most overexpressed genes, 50% had a chromosomal locus that was amplified in the comparative genomic hybridization data. Although the list of most over- and underexpressed genes was similar between the nodules of different size, the gene set enrichment analysis identified different pathways associated with AIMAH that corresponded to the size; the smaller nodules were mainly enriched for metabolic pathways, whereas p53 signaling and cancer genes were enriched in larger nodules. Confirmatory studies demonstrated that BCL2, E2F1, EGF, c-KIT, MYB, PRKCA, and CTNNB1 were overexpressed in the larger nodules at messenger and/or protein levels. Chromosomal enrichment analysis showed that chromosomes 20q13 and 14q23 might be involved in progression of AIMAH from smaller to larger tumors.
Integrated transcriptomic and genomic data for AIMAH provides supporting evidence to the hypothesis that larger adrenal lesions, in the context of this chronic, polyclonal hyperplasia, accumulate an increased number of genomic and, subsequently, transcript abnormalities. The latter shows that the disease appears to start with mainly tissue metabolic derangements, as suggested by the study of the smaller nodules, but larger lesions showed aberrant expression of oncogenic pathways.
大结节性肾上腺皮质疾病或 ACTH 非依赖性大结节性肾上腺增生(AIMAH)是一种临床表现和遗传上具有异质性的疾病。
对来自同一 AIMAH 患者不同结节的样本进行全基因组表达谱分析和寡核苷酸阵列比较基因组杂交变化分析。采用定量 RT-PCR 和染色法验证 mRNA 阵列数据。
与同一患者的较小结节相比,较大结节中染色体获得更为频繁。在 50 个过表达基因中,有 50%的基因在比较基因组杂交数据中存在染色体位置扩增。尽管大小不同的结节之间的过表达和低表达基因列表相似,但基因集富集分析确定了与 AIMAH 相关的不同途径,这些途径与大小相对应;较小的结节主要富集代谢途径,而较大的结节中 p53 信号和癌症基因富集。验证性研究表明,BCL2、E2F1、EGF、c-KIT、MYB、PRKCA 和 CTNNB1 在信使和/或蛋白质水平上在较大的结节中过表达。染色体富集分析表明,20q13 和 14q23 染色体可能参与了 AIMAH 从小肿瘤向大肿瘤的进展。
AIMAH 的综合转录组学和基因组数据为较大的肾上腺病变在这种慢性多克隆增生的背景下积累越来越多的基因组和随后的转录异常的假说提供了支持证据。后者表明,该疾病似乎首先表现为组织代谢紊乱,正如较小结节的研究所示,但较大的病变表现出致癌途径的异常表达。